Hansa Biopharma — December 2024

[LP90]

Godmorgen super med gode resultater men det ses bare ikke rigtig på kursen
hvem havde troet vi ultimo 2024 skulle ligge i kurs 28 ? ja jeg havde ikke

[exitnu]

Lidt det samme kunne vi jo også have sagt, da Zealand Pharma lå i under kurs 75 i 2022

[exitnu]

Vi kan da sagtens se hen i mod en 10 - 20 dobling af kursen indenfor 2-3 år hvis alt udspiller sig i den helt rigtige retning.

[exitnu]

... fx også lykkes med HNSA-5487 (næste generations IgG-cleaving enzym) som har potentiale for gentagen dosering.

[exitnu]

2024-12-18 03:00:02: ActusRayPartners Limited har rapporterat in en ny position i Hansa Biopharma AB. Positionen uppgår till motsvarande -222 367 aktier (0,50% av kap.) per 2024-12-17.

[exitnu]

Kempen höjer riktkursen för Hansa Biopharma till 100 kronor (90), upprepar köp - BN

[LP90]

exitnu tak for dine faglige indlæg

[exitnu]

Også tak for dine input og morgenhilsner

[LP90]

Godmorgen

[Urban]

Er der nogen, der har et aktuelt shorting overblik på
Hansa Biopharma? Evt. link.

[Urban]

Shorting Hansa Biopharma https://shortnordic.com/details_company.php?company=hansa biopharma&land=sweden

[Urban]

Potentielle gode chancer for en faldende shorting på det nuværende
kursniveau? Kommentar?

[exitnu]

Tilsyneladende en ny Hansa Biopharma hjemmeside:

Hansa Biopharma - Home

We develop lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

(www.hansabiopharma.com)

[exitnu]

Shortposition steget en smule

[exitnu]

... skal jo også købes tilbage

[Urban]

FYI Hansa Biopharma
shorting: https://shortnordic.com/history_company.php?selskapsnavn=HANSA BIOPHARMA&land=sweden

[LP90]

Godmorgen

[exitnu]

Hansa Biopharma GBS has advanced to become a value driver

(Redeye Research Note 2024-12-20 12:34)

Just a moment...

(www.redeye.se)

[exitnu]

Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS. This is an orphan indication, and GBS is an acute disease in patients that tends to become non-ambulatory within weeks rapidly. If approved, Imflifidase will expand into a dynamic market. We increase our base case to SEK 130 from 125 (Bull SEK 220, Bear SEK 15).

[exitnu]

... In our view, GBS is also adding a business opportunity that can attract institutional interest in future direct share issues, potential commercial business partners, and increased interest in engaging with Hansa in structured finance solutions.